Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care

In BRAF(V600mut) metastatic melanoma, the combination of BRAF and MEK inhibitors (BRAFi, MEKi) has undergone multiple resistance mechanisms, limiting its clinical benefit and resulting in the need for response predicting biomarkers. Based on phase III clinical trial data, several studies have previo...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cancers (Basel)
Main Authors: Louveau, Baptiste, Jouenne, Fanelie, Reger de Moura, Coralie, Sadoux, Aurelie, Baroudjian, Barouyr, Delyon, Julie, Herms, Florian, De Masson, Adele, Da Meda, Laetitia, Battistella, Maxime, Dumaz, Nicolas, Lebbe, Celeste, Mourah, Samia
Format: Artigo
Sprog:Inglês
Udgivet: MDPI 2019
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6721518/
https://ncbi.nlm.nih.gov/pubmed/31426590
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11081203
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker